Back HCV Treatment AASLD 2011: HCV Direct-Acting Antivirals Boost Interferon Response Rates

AASLD 2011: HCV Direct-Acting Antivirals Boost Interferon Response Rates

alt

Several studies at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) last week in San Francisco showed that adding experimental direct-acting antiviral (DAA) agents to pegylated interferon plus ribavirin increases virological response rates for people with chronic hepatitis C.

BI 201335 Performs Well with Standard Therapy

TMC435 + Pegylated Interferon/Ribavirin

PSI-7977 + Pegylated Interferon/Ribavirin

12-week Daclatasvir + Pegylated Interferon/Ribavirin

Danoprevir + Pegylated Interferon/Ribavirin